SEVERE MUCOCUTANEOUS CANDIDIASIS

Clinical trials for SEVERE MUCOCUTANEOUS CANDIDIASIS explained in plain language.

Never miss a new study

Get alerted when new SEVERE MUCOCUTANEOUS CANDIDIASIS trials appear

Sign up with your email to follow new studies for SEVERE MUCOCUTANEOUS CANDIDIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Drug trial targets Body's Self-Attacking immune cells

Disease control Completed

This study tested whether a drug called rituximab could safely treat rare diseases where the immune system mistakenly attacks the body's own proteins. Seven adults with these conditions, who were not helped by standard treatments, received rituximab infusions over six months. The…

Matched conditions: SEVERE MUCOCUTANEOUS CANDIDIASIS

Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

SEVERE MUCOCUTANEOUS CANDIDIASIS

Get alerted when new SEVERE MUCOCUTANEOUS CANDIDIASIS trials appear

Drug trial targets Body's Self-Attacking immune cells